

Recombinant Murine soluble Tumor Necrosis Factor Receptor Type I/TNFRSF1A

Information

AA Sequence IHPSGVTGLV PSLGDREKRD SLCPQGKYVH SKNNSICCTK CHKGTYLV: CPSPGRDTVC RECEKGTFTA SQNYLRQCLS CKTCRKEMSQ VEISPCQ DTVCGCKENQ FQRYLSETHF QCVDCSPCFN GTVTIPCKET QNTVCNCF FFLRESECVP CSHCKKNEEC MKLCLPPPLA NVTNPQDSGT A Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Use a manual defrost freezer and avoid repeated freeze-thaw cycles - 12 months from date of receipt, -20 to -70 °C as supplied - 1 month, 2 to 8 °C under sterile conditions after reconstitution - 3 months, -20 to -70 °C under sterile conditions after reconstitution Formulation Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. We recommend that this vial be briefly centrifuged prior to opening to bring contents to the bottom. Reconstitute in sterile distilled water or aqueous buf containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Furth dilutions should be made in appropriate buffered solutions. Fully biologically active when compared to standard. The ED as determined	normation			
Source Escherichia coli. Approximately 21.1 kDa, a single non-glycosylated polypeptide chain conta 191 amino acids. IHPSGVTGLV PSLGDREKRD SLCPQGKYVH SKNNSICCTK CHKGTYLV: CPSPGRDTVC RECEKGTFTA SQNYLRQCLS CKTCRKEMSQ VEISPCQ. DTVCGCKENQ FQRYLSETHF QCVDCSPCFN GTVTIPCKET QNTVCNCFFLRESECVP CSHCKKNEEC MKLCLPPPLA NVTNPQDSGT A Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Use a manual defrost freezer and avoid repeated freeze-thaw cycles - 12 months, 2 to 8 °C under sterile conditions after reconstitution - 3 months, -20 to -70 °C under sterile conditions after reconstitution Formulation Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. We recommend that this vial be briefly centrifuged prior to opening to bring contents to the bottom. Reconstitute in sterile distilled water or aqueous buf containing 0.1 % BSA to a concentration of 0.1-1 0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Furth dilutions should be made in appropriate buffered solutions. Fully biologically active when compared to standard. The ED as determined its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 1 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 0.1 ng/mL of rMuTNF-α. Shipping Condition Gel pack.	Gene ID	21937		
Source Escherichia coli. Approximately 21.1 kDa, a single non-glycosylated polypeptide chain conta 191 amino acids. IHPSGVTGLV PSLGDREKRD SLCPQGKYVH SKNNSICCTK CHKGTYLV: CPSPGRDTVC RECEKGTFTA SQNYLRQCLS CKTCRKEMSQ VEISPCQ. DTVCGCKENQ FQRYLSETHF QCVDCSPCFN GTVTIPCKET QNTVCNCFFLRESECVP CSHCKKNEEC MKLCLPPPLA NYTNPQDSGT A Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Use a manual defrost freezer and avoid repeated freeze-thaw cycles - 12 months from date of receipt, -20 to -70 °C as supplied - 1 month, 2 to 8 °C under sterile conditions after reconstitution - 3 months, -20 to -70 °C under sterile conditions after reconstitution Formulation Formulation Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. We recommend that this vial be briefly centrifuged prior to opening to bring contents to the bottom. Reconstitute in sterile distilled water or aqueous buf containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Furth dilutions should be made in appropriate buffered solutions. Fully biologically active when compared to standard. The ED as determined its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 1 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 0.1 ng/mL of rMuTNF-α. Shipping Condition Gel pack.	Accession #	P25118		
Approximately 21.1 kDa, a single non-glycosylated polypeptide chain conta 191 amino acids. IHPSGVTGLV PSLGDREKRD SLCPQGKYVH SKNNSICCTK CHKGTYLV: CPSPGRDTVC RECEKGTFTA SQNYLRQCLS CKTCRKEMSQ VEISPCQ. DTVCGCKENQ FQRYLSETHF QCVDCSPCFN GTVTIPCKET QNTVCNCFFLRESECVP CSHCKKNEEC MKLCLPPPLA NVTNPQDSGT A Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Use a manual defrost freezer and avoid repeated freeze-thaw cycles - 12 months from date of receipt, -20 to -70 °C as supplied - 1 month, 2 to 8 °C under sterile conditions after reconstitution - 3 months, -20 to -70 °C under sterile conditions after reconstitution Formulation Formulation Reconstitution Reconstitution Reconstitution Biological Activity Biological Activity Approximately 21.1 kDa, a single non-glycosylated polypeptide chain contains 191 amino acids. HPSGVTGLV PSLGDREKRD SLCPQGKYVH SKNNSICCTK CHKGTYLV: CPSKTON CHKGTYLV: CPSKTON CHKGTYLV: CPSKTON CHKGTYLV: CPSKTON CHKGTYLV: SKNNSICCTK CHKGTYLV: CPSKTON CHKGTYLV: CPSKTON CHKGTYLV: CPSKTON CHKGTYLV: CPSKTON CHKGTYLV: CPSKTON CHKGTYLV: CPSKTON CHKGTYLV: SKNNSICCTK CHKGTYLV: CPSKTON CHKGTYLV: SKNNSICCTK CHKGTYLV: CPSKTON CHKGTYLV: SKNNSICCTK CHKGTYLV: CPSKTON CHKGTYLV:	Alternate Names			
191 amino acids. IHPSGVTGLV PSLGDREKRD SLCPQGKYVH SKNNSICCTK CHKGTYLV: CPSPGRDTVC RECEKGTFTA SQNYLRQCLS CKTCRKEMSQ VEISPCQ, DTVCGCKENQ FQRYLSETHF QCVDCSPCFN GTVTIPCKET QNTVCNCF FFLRESECVP CSHCKKNEEC MKLCLPPPLA NVTNPQDSGT A Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Use a manual defrost freezer and avoid repeated freeze-thaw cycles - 12 months from date of receipt, -20 to -70 °C as supplied - 1 month, 2 to 8 °C under sterile conditions after reconstitution - 3 months, -20 to -70 °C under sterile conditions after reconstitution Formulation Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. We recommend that this vial be briefly centrifuged prior to opening to bring contents to the bottom. Reconstitute in sterile distilled water or aqueous buf containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Furth dilutions should be made in appropriate buffered solutions. Fully biologically active when compared to standard. The ED as determined its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 1 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 0.1 ng/mL of rMuTNF-α. Shipping Condition Gel pack.	Source	Escherichia coli.		
CPSPGRDTVC RECEKGTFTA SQNYLRQCLS CKTCRKEMSQ VEISPCQDTVCGCKENQ FQRYLSETHF QCVDCSPCFN GTVTIPCKET QNTVCNCFFFLRESECVP CSHCKKNEEC MKLCLPPPLA NVTNPQDSGT A Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Use a manual defrost freezer and avoid repeated freeze-thaw cycles - 12 months from date of receipt, -20 to -70 °C as supplied - 1 month, 2 to 8 °C under sterile conditions after reconstitution - 3 months, -20 to -70 °C under sterile conditions after reconstitution Formulation Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. We recommend that this vial be briefly centrifuged prior to opening to bring contents to the bottom. Reconstitute in sterile distilled water or aqueous but containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Furth dilutions should be made in appropriate buffered solutions. Fully biologically active when compared to standard. The ED as determined its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 1 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 0.1 ng/mL of rMuTNF-α. Shipping Condition Gel pack.	M.Wt	Approximately 21.1 kDa, a single non-glycosylated polypeptide chain containing 191 amino acids.		
Use a manual defrost freezer and avoid repeated freeze-thaw cycles - 12 months from date of receipt, -20 to -70 °C as supplied - 1 month, 2 to 8 °C under sterile conditions after reconstitution - 3 months, -20 to -70 °C under sterile conditions after reconstitution Formulation Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. We recommend that this vial be briefly centrifuged prior to opening to bring contents to the bottom. Reconstitute in sterile distilled water or aqueous buf containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Furth dilutions should be made in appropriate buffered solutions. Fully biologically active when compared to standard. The ED as determined its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 1 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 0.1 ng/mL of rMuTNF-α. Shipping Condition	AA Sequence	IHPSGVTGLV PSLGDREKRD SLCPQGKYVH SKNNSICCTK CHKGTYLVSD CPSPGRDTVC RECEKGTFTA SQNYLRQCLS CKTCRKEMSQ VEISPCQADK DTVCGCKENQ FQRYLSETHF QCVDCSPCFN GTVTIPCKET QNTVCNCHAG FFLRESECVP CSHCKKNEEC MKLCLPPPLA NVTNPQDSGT A		
- 12 months from date of receipt, -20 to -70 °C as supplied - 1 month, 2 to 8 °C under sterile conditions after reconstitution - 3 months, -20 to -70 °C under sterile conditions after reconstitution Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. We recommend that this vial be briefly centrifuged prior to opening to bring contents to the bottom. Reconstitute in sterile distilled water or aqueous buf containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Furth dilutions should be made in appropriate buffered solutions. Fully biologically active when compared to standard. The ED as determined its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 1 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 0.1 ng/mL of rMuTNF-α. Shipping Condition Gel pack.	Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.		
We recommend that this vial be briefly centrifuged prior to opening to bring contents to the bottom. Reconstitute in sterile distilled water or aqueous buf containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Furth dilutions should be made in appropriate buffered solutions. Fully biologically active when compared to standard. The ED as determined its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 1 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 0.1 ng/mL of rMuTNF-α. Shipping Condition Gel pack.	Stability & Storage	 12 months from date of receipt, -20 to -70 °C as supplied 1 month, 2 to 8 °C under sterile conditions after reconstitution 		
 Reconstitution BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Furth dilutions should be made in appropriate buffered solutions. Fully biologically active when compared to standard. The ED as determined its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 1 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 0.1 ng/mL of rMuTNF-α. Shipping Condition 	Formulation	Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.		
 Biological Activity its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 1 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 0.1 ng/mL of rMuTNF-α. Shipping Condition Gel pack. 	Reconstitution	should be apportioned into working aliquots and stored at ≤ -20 °C. Further		
30	Biological Activity			
Handling Centrifuge the vial prior to opening.	Shipping Condition	Gel pack.		
	Handling	Centrifuge the vial prior to opening.		
Usage For Research Use Only! Not to be used in humans.	Usage	For Research Use Only! Not to be used in humans.		

Components and Storage

Components	5µg	100µg	500µg
Recombinant Murine soluble Tumor Necrosis Factor Receptor Type I/TNFRSF1A	5µg	100µg	500µg

Use a manual defrost freezer and avoid repeated freeze-thaw cycles

- 12 months from date of receipt, -20 to -70 °C as supplied
- 1 month, 2 to 8 °C under sterile conditions after reconstitution
- 3 months, -20 to -70 °C under sterile conditions after reconstitution

Quality Control

	Name of the second seco	nknow.
Purity	> 97 % by SDS-PAGE and HPLC analyses.	Particular de la companya del companya del companya de la companya
Endotoxin	Less than 0.1 EU/µg of rMusTNF RI/TNFRS	TA as determined by LAL method.

Description

Reference





10





APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com